• European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use in the EU; Countries Outside of the EU through the EU-M4all (Previously Article 58) Procedure
• Takeda Intends to Submit Regulatory Filings in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand During 2021
• TAK-003 is Being Studied for the Prevention of Dengue Due to any Dengue Virus Serotype in Individuals Ages Four to 60

OSAKA, JAPAN, and CAMBRIDGE, MASSACHUSETTS – Media OutReach – 26 March 2021 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency (EMA) has accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003) which is being investigated for the prevention of dengue due to any dengue virus serotype in individuals ages four to 60. Takeda intends to submit regulatory filings in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand during 2021.

“Submission of regulatory filings for our dengue vaccine candidate, TAK-003, marks an important development for people who are living in or traveling to communities burdened by the threat of dengue,” said Derek Wallace, VP, Dengue Global Program Leader at Takeda. “Dengue outbreaks, which result in half a million hospitalizations globally each year, can overwhelm communities and governments because of the broad impact on the health care system. With limited options to prevent the disease, there is a pressing need for widely available dengue vaccines. Takeda is committed to working with regulatory authorities and recommending bodies to support evaluation of our submissions and achieve access for TAK-003.”

Takeda is participating in the EMA’s first-ever parallel assessment of a medicinal product for use in the European Union (EU), and through the EU-M4all (previously Article 58) procedure for countries outside of the EU. Along with the scientific opinion issued by the Committee for Medicinal Products for Human Use (CHMP), national regulators in countries participating in the EU-M4all procedure will conduct their own assessments to determine if national marketing authorizations for TAK-003 are granted. Takeda is also seeking approval of TAK-003 in dengue-endemic countries that are not participating in the EU-M4all procedure.

Regulatory submissions for TAK-003 include long-term safety and efficacy data through 36 months from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. Takeda intends to present and publish details of the 36-month data at a scientific meeting and in a peer-reviewed journal this year.

Takeda also intends to submit regulatory filings in the United States, followed by additional countries in Asia and Latin America.

EU-M4all^[i]

EU-M4all (or EU-Medicines for all) is a procedure designed to facilitate patient access to essential medicines or vaccines intended to prevent or treat diseases of major public health interest. Through the EU-M4all procedure (previously known as the Article 58 procedure), the EMA, in cooperation with the World Health Organization (WHO), can provide scientific opinion on medicines and vaccines for public health priority diseases that are intended for markets outside of the EU.

About TAK-003

Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses.^[ii] Clinical Phase 2 data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes, in both seropositive and seronegative participants, which persisted through 48 months after vaccination, and the vaccine was found to be generally safe and well tolerated.^[iii] The pivotal Phase 3 TIDES trial met its primary endpoint of overall vaccine efficacy (VE) against virologically confirmed dengue (VCD) at 12 months follow-up and all secondary endpoints at 18 months follow-up for which there were a sufficient number of dengue cases, including VE against hospitalized dengue and VE in baseline seropositive and baseline seronegative individuals.^[iv],[v] Efficacy varied by serotype. The results demonstrated TAK-003 was generally well tolerated, and there have been no important safety risks observed to date.

About the Phase 3 TIDES (DEN-301) Trial

The double-blind, randomized, placebo-controlled Phase 3 TIDES trial is evaluating the safety and efficacy of two doses of TAK-003 in the prevention of laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in children and adolescents.^[iv] The TIDES trial is Takeda’s largest interventional clinical trial to date and enrolled over 20,000 healthy children and adolescents ages four to 16 years living in dengue-endemic areas. Study participants were randomly assigned to receive either TAK-003 0.5 mL or placebo by subcutaneous injection on Day 1 and Day 90.^[iv] The study is comprised of five parts. Part 1 and the primary endpoint analysis evaluated vaccine efficacy (VE) and safety through 15 months after the first dose (12 months after the second dose).^[iv] Part 2 continued for an additional six months to complete the assessment of the secondary endpoints of VE by serotype, baseline serostatus and disease severity, including VE against hospitalized dengue.^[iv] Part 3 is evaluating VE and long-term safety by following participants for an additional two and a half to three years.^[vi] Part 4 will evaluate safety for 13 months following booster vaccination and Part 5 will evaluate long-term safety for one year after completion of Part 4.^[vi]

The trial is taking place at sites in dengue-endemic areas in Latin America (Brazil, Colombia, Panama, the Dominican Republic and Nicaragua) and Asia (Philippines, Thailand and Sri Lanka) where there are unmet needs in dengue prevention and where severe dengue is a leading cause of serious illness and death among children.^[iv] Baseline blood samples were collected from all individuals participating in the trial to allow for evaluation of safety and efficacy based on serostatus. Takeda and an independent Data Monitoring Committee of experts are actively monitoring safety on an ongoing basis.

About Dengue

Dengue is the fastest spreading mosquito-borne viral disease and was one of the WHO’s top 10 threats to global health in 2019.^[vii],[viii] Dengue is mainly spread by Aedes aegypti mosquitoes and, to a lesser extent, Aedes albopictus mosquitoes. It is caused by any of four dengue virus serotypes, each of which can cause dengue fever or severe dengue. The prevalence of individual serotypes varies across different geographies, countries, regions, seasons and over time.^[ix] Recovery from infection by one serotype provides lifelong immunity against only that serotype, and later exposure to any of the remaining serotypes is associated with an increased risk of severe disease.

Dengue is pandemic prone, and outbreaks are observed in tropical and sub-tropical areas and have recently caused outbreaks in parts of the continental United States and Europe.^[x],[xi] Approximately half of the world now lives under the threat of dengue, which is estimated to cause 390 million infections and around 20,000 deaths globally each year.^[x],[xi] The dengue virus can infect people of all ages and is a leading cause of serious illness among children in some countries in Latin America and Asia.^[x]

Takeda’s Commitment to Vaccines

Vaccines prevent 2 to 3 million deaths each year and have transformed global public health.^[xiii] For the past 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, COVID-19, Zika and norovirus. Takeda’s team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs. For more information, visit www.takedavaccines.com/.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/ reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

References

^[i] The European Medicines Agency. Medicines for use outside the EU — EU-M4all. July 2020. Retrieved March 2021.

^[ii] Huang CY-H, et al. Genetic and phenotypic characterization of manufacturing seeds for tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis. 2013;7:e2243.

^[iii] Tricou, V, Sáez-Llorens X, et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Lancet. 2020. doi:10.1016/S0140-6736(20)30556-0.

^[iv] Biswal S, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. 2019; 2019;381:2009-2019.

^[v] Biswal S, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomized, placebo controlled, phase 3 trial. Lancet. 2020. 2020;395:1423-1433.

^[vi] ClinicalTrials.Gov. Efficacy, Safety and Immunogenicity of Takeda’s Tetravalent Dengue Vaccine (TDV) in Healthy Children (TIDES). Retrieved March 2021.

^[vii] World Health Organization. Factsheet. Dengue and Severe Dengue. April 2019. Retrieved February 2021.

^[viii] World Health Organization. Ten threats to global health in 2019. 2019. Retrieved February 2021.

^[ix] Guzman MG, et al. Dengue: a continuing global threat. Nature Reviews Microbiology. 2010;8:S7-S16.

^[x] Knowlton K, et al. Mosquito-Borne Dengue Fever Threat Spreading in the Americas. The Natural Resources Defense Council (NRDC). 2009. Retrieved February 2021.

^[xi] Chan E, et al. Using web search query data to monitor dengue epidemics: a new model for neglected tropical disease surveillance. PLoS Negl Trop Dis. 2011;5:e1206.

^[xii] Centers for Disease Control and Prevention. About Dengue: What You Need to Know. May 2019. Retrieved February 2021.

^[xiii] UNICEF. Vaccination and Immunization Statistics. 2019. Retrieved February 2021.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

/>This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/ reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Chair of the WorldGBC, Mr William McDonough, Ms Meaghan Lloyd of Gehry Partners and Professor Jiang Yi from Tsinghua University will be on the Jury Panel to offer professional insights to the contestants

HONG KONG SAR – Media OutReach – 26 March 2021 – The Hong Kong Green Building Council (HKGBC), a non-profit organisation dedicated to transforming the city into a greener built environment, announced today the launch of Hong Kong’s first “Advancing Net Zero” Ideas Competition along with Swire Properties (1972.HK) as Principal Partner of the project.

The Competition invites international industry stakeholders, designers, academia, and technology experts to contribute ideas on how to move Hong Kong’s building sector towards carbon neutrality – a net-zero position – for a sustainable future. Winners and shortlisted candidates will be eligible for a total of HK$1.2 million in prize money.

Some world-renowned names are sitting on the influential Jury Panel which include Ms Tanya Cox, Chair of the World Green Building Council; Professor Jiang Yi, Director of the Building Energy Research Centre of Tsinghua University; Mr William McDonough, architect and globally recognised leader in sustainable development and design, and founding partner of William McDonough + Partners; and Ms Meaghan Lloyd, Partner at Gehry Partners, the acclaimed firm founded by Pritzker Prize Laureate Frank Gehry.

The effects of global warming are already stressing our ecosystem, so combating climate change, and reducing our carbon footprint has become a vitally important mission for the entire global community. A special report published by the UN Intergovernmental Panel on Climate Change (IPCC) in 2018, stated that total man-made greenhouse gas (GHG) emissions need to halve by 2030 and reach a “net-zero” position by around 2050 in order to limit global warming to less than 1.5 degrees and avoid a climate catastrophe for our planet.

According to the World Green Building Council (WorldGBC), buildings currently account for 39% of energy-related carbon emissions globally. In densely populated Hong Kong, however, more than 60% of carbon emissions are ascribed to buildings, and 15% to 20% of the lifecycle carbon footprint of buildings is attributable to construction. Reducing these figures through green building practices is therefore critical.

“Advancing Net Zero” (ANZ) is a worldwide initiative launched by the WorldGBC to promote net-zero carbon buildings. This is in line with the Hong Kong Government’s environmental target to achieve carbon neutrality by 2050.

The ANZ Ideas Competition consists of two categories: (i) Future Building and (ii) Existing Building. Ar. Ada Fung, Chairperson of the Organising Committee of the ANZ Ideas Competition said, “The overall aim is to stimulate innovative and valuable carbon reduction insights from multi-disciplinary professionals, raise public awareness, generate new ideas and solutions, enhance learning and knowledge sharing on Advancing Net Zero, and to push the boundaries to design future-ready buildings and retrofit existing building stock to advance net zero emissions economy by 2050. The Competition also aims to accelerate the building industry to adopt and develop low/zero carbon design and technologies, and to stimulate the reviews of current regulations and code of practices to facilitate the development of eco-technology where appropriate.”

Mr Cheung Hau-wai, Chairman of the Hong Kong Green Building Council said, “Hong Kong is one of the world’s top tier metropolises and is famous for its high-rise architecture. Its subtropical climate with immense building density means it is crucial for us to implement low carbon strategies and generate energy-efficient design solutions for buildings. We look forward to interacting and exchanging ideas with multi-talented experts around the world in the hope of creating a low carbon future for our community.”

Mrs Elizabeth Kok, Director and Senior Advisor of Swire Properties Limited said, “As part of Swire Properties’ long-term commitment to sustainable development, we’re excited to be supporting the first ANZ Ideas Competition, which can inspire our industry to take action and bring positive change to the built environment and beyond. As Principal Partner, we’re supporting this unique initiative by offering extensive data harnessed from two of our advanced buildings at Taikoo Place; this will help facilitate in-depth analysis of real cases, and foster original solutions that can advance to net zero buildings in a high-density city like Hong Kong.”

Leading industry influencers as Jury Panel

The “Advancing Net Zero” Ideas Competition has been well received by local and international industry leaders who also sit on the Jury Panel. Ms Tanya Cox, Chair of the World Green Building Council said, “Accelerating a net zero built environment is one of the surest ways to combat climate change. To unlock the 1.5 degrees ambition of the Paris Agreement, we need to encourage and incentivise net zero solutions. HKGBC’s “Advancing Net Zero” Ideas Competition provides the motivation we need to bring these ambitious ideas and innovation to life.”

About the HKGBC “Advancing Net Zero” Ideas Competition: https://anzideascompetition.hkgbc.org.hk

About the HKGBC: www.hkgbc.org.hk.

About Swire Properties and its SD efforts: www.swireproperties.com.

M1’s made-to-measure Bespoke mobile plans are the next step in the journey to revolutionise Singapore’s telecommunications industry. Reflected in the newly unveiled human-centred stories behind the ‘Be’ campaign, these incredibly flexible mobile plans give customers the freedom to be themselves.

SINGAPORE – Media OutReach – 26 March 2021 – Following the recent announcement of M1 Limited’s rebranding to drive transformation, the company is delivering on its goal to rejuvenate Singapore’s telecommunications landscape. Featuring a selection of made-to-measure Bespoke plans, these directly address customer demand for personalisation and flexibility. With this fresh, customer-first approach, M1 stands true to its name of being Singapore’s first digital network operator.

Made-to-Measure Mobile Plans

M1’s new Bespoke mobile plans aim to meet customers’ desire for greater personalisation. Whether looking for a mobile device or a suitable plan, these three made-to-measure offerings – Bespoke Flexi, Bespoke SIM-only, and Bespoke Contract – can be customised to fit individual needs.

Bespoke Flexi provides customers with greater flexibility in every respect, as they can dictate their upfront device payment and choose to settle their balance between 12 and 36 months. With no strings attached, users now have the freedom to upgrade or downgrade their plan whenever they want. Also, customers can change their monthly data and talk time either in-store or using the My M1+ app without fear of encountering any early termination or admin fees.

M1’s Bespoke SIM-only mobile plan offers customers an adaptable, contract-free experience. With the ability to change plans from month-to-month, users can take full advantage of M1’s latest products. Plus, customers using the M1+ app now have a convenient slider to balance their data, talk time and price on the fly.

Finally, Bespoke Contract’s updated data bundles provide customers with even more value as the new base plan includes 20GB. Alongside three fresh add-ons, customers can build a plan suited to their budget and needs.

Be Free with M1

M1 has launched the first stories from the ‘Be’ campaign in conjunction with their re-energised mobile plans. Featuring seven Singaporeans with an unmistakable drive to tread their own path, this campaign reflects the spirit of individuality that M1 wants to celebrate. Across Singapore’s BYOBottle movement founder, a guitar-shredding grandma and one of the world’s top doll collectors, in collaboration with M1, these personal tales highlight the importance of freedom and having the confidence to simply be who you are.

Advancing Singapore’s Digital Landscape

Supported by a tech-focused transformation both in-store and via its mobile app, M1’s reinvigorated nature is already evolving the digital landscape for its customers, changing how Singaporeans engage with telecommunications.

About M1

M1, a subsidiary of Keppel Corporation, is Singapore’s first digital network operator, providing a suite of communications services, including mobile, fixed line and fibre offerings, to over two million customers.

Since the launch of its commercial services in 1997, M1 has achieved many firsts – becoming one of the first operators to be awarded one of Singapore’s two nationwide 5G standalone network license, first operator to offer nationwide 4G service, as well as ultra high-speed fixed broadband, fixed voice and other services on the Next Generation Nationwide Broadband Network (NGNBN).

HONG KONG SAR – Media OutReach – 26 March 2021 – Owl Square has recently signed a nearly 10-year lease for the entire building located at 20 Luard Road, Wanchai, with a floor area of 22,300 square feet and an estimated leasable area of over 19,000 square feet. The serviced apartment in Wan Chai is designed to provide privacy, convenience, and safekeeping of your belongings. Whether it’s the location of power outlets or USB ports, or the doors opening to the left or right, these details matter. The company also have a serviced apartment in sheung wan that’s close to central to cater the needs of the corporate workforce in terms of living and working in the heart of the city.

The current clientele of Owl Square’s coliving or serviced apartment rental properties are mainly locals, expatriates, students, and professionals. Since the property type provides a variety of types of rental packages and offers flexible pricing model, the overall occupancy rate has reached over 90% even under the impact of the epidemic.

Owl Square was founded in 2017 by its founder, Max Poon, after raising nearly $100 million from a Hong Kong listed company and Hong Kong famous families. With 14 serviced apartment locations across Hong Kong Island and Kowloon, Owl Square offers nearly 2,000 beautifully decorated small to medium sized units with flexible leases, rent inclusive of management fees, utilities, internet access and weekly housekeeping and laundry services. In addition, Owl Square welcomes tenants from all walks of life and offers affordable, comfortable, convenient and safe housing to help solve housing problems for all types of residents. It is a fun place for all residents to live, combining the comforts of home with the elements of modern living.